-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Ravi Salgia, MD, PhD
Ravi Salgia, MD, PhD, was awarded the IACA Award for Outstanding Contributions to Oncology by the Indo-American Cancer Association (IACA). This award is given to medical oncologists and researchers who have helped define modern cancer medicine. Dr. Salgia is the Arthur & Rosalie Kaplan Chair in Medical Oncology and Therapeutics Research at City of Hope,…
-
Mental Health Really Matters: Lung Cancer Diagnosis Has the Greatest Risk of Suicide among Cancer Patients in USA – SEER Database Analysis
By Mohamed Rahouma, MD, Mohamed Kamel, MD, and Jeffrey L. Port, MD A cancer diagnosis can be overwhelming, especially if someone has limited social support. Previous international reports have indicated that the distress associated with a cancer diagnosis could lead to a higher suicide rate. This was evident in respiratory and breast cancers in Denmark,1…
-
Solange Peters, MD, PhD
Solange Peters, MD, PhD, was elected President for 2020-2021 of the European Society for Medical Oncology (ESMO). Professor Peters is Head of the Medical Oncology Service, Chair of Thoracic Oncology, Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
-
Naiyer A. Rizvi, MD
Naiyer A. Rizvi, MD, was named to the ARMO BioSciences, Inc., Board of Directors, Redwood City, US. Dr. Rizvi is Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Division of Hematology and Oncology, Columbia University Medical Center, NY, US, and holds the Price Chair in Clinical Translational Research.
-
David R. Gandara, MD
David R. Gandara, MD, was honored as the lung cancer “Giant of Cancer Care” in the 2017 Giants of Cancer Care® recognition program by OncLive. Awardees are selected by their peers for advancing the field of oncology by contributions in research and clinical practice. Dr. Gandara is Professor and Director of Thoracic Oncology at UC…
-
Promise of Smoke-Free Future Falls Short
Editor’s Note: IASLC Lung Cancer News is pleased to publish this article as part of its continuing focus on the expansion of “combustible tobacco” (cigarettes) to include non-combustible products and related issues.* Philip Morris International (PMI), one of the leading international tobacco companies, recently pledged on its website to build a smoke-free future.1 In its…
-
Roman V. Petrov, MD, PhD
Roman V. Petrov, MD, PhD, has been appointed Assistant Professor, Department of Surgical Oncology, Fox Chase Cancer Center; and Assistant Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, US. Prior to his appointment, Dr. Petrov served as an Attending Physician and Chief of the Department of Thoracic Surgery at Memorial…
-
Gideon M. Blumenthal, MD
Gideon M. Blumenthal, MD was named Acting Deputy Director, Office of Hematology & Oncology Products, US Food and Drug Administration, Silver Spring, US. Prior to this appointment, Dr. Blumenthal was Clinical Team Leader for Thoracic Oncology and Head and Neck Cancer and Scientific Liaison for Lung Cancer in the Division of Oncology Products, Office of…
-
Q&A with Alice Shaw, MD, PhD
Based on global ALEX, has crizotinib been relegated to the therapeutic scrapheap when it comes to patients with ALK rearrangements? Or does it retain some role? The global ALEX study, presented at ASCO 2017 and published simultaneously in the NEJM, compared alectinib head-to-head with crizotinib in previously untreated, advanced ALK-positive NSCLC. The study met its…
-
Q&A with Benjamin Solomon, MBBS, PhD, FRACP
Please give us a global perspective on the results of global ALEX. Will alectinib definitively displace crizotinib or ceritinib as the first-line treatment for ALK-rearranged non-small cell lung cancer (NSCLC)? The rapid pace of development of ALKtargeted therapies in NSCLC in the last decade has transformed outcomes for patients with ALK-rearranged NSCLC. Crizotinib, the first…
View ILCN Archives
Provider Resources
Popular Articles